Ionis (NASDAQ: IONS) EVP logs RSU vesting, PRSU grant and tax sales
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ionis Pharmaceuticals executive Joseph Baroldi reported equity award activity and related share sales. On 01/15/2026, restricted stock units vested, resulting in the acquisition of 17,037 shares of common stock directly and 2,850 shares indirectly through his spouse at an exercise price of $0.0 per share. Following these transactions, he held 47,338 common shares directly and 5,921 shares indirectly through his spouse.
On 01/16/2026, he reported sales of 6,907 directly held shares at a weighted average price of $75.75 and 1,149 indirectly held shares at $75.78, described as automatic sales to cover tax withholding obligations. Separately, on 01/15/2026 he received a grant of 25,800 performance restricted stock units that may vest after a three‑year performance period, as well as additional restricted stock unit grants for himself and his spouse under the company’s equity incentive plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 8,056 shares ($610,276)
Net Sell
9 txns
Insider
Baroldi Joseph
Role
EVP, Chief Business Officer
Sold
8,056 shs ($610K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,907 | $75.75 | $523K |
| Sale | Common Stock | 1,149 | $75.78 | $87K |
| Grant/Award | Performance Restricted Stock Units | 25,800 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 17,037 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 9,675 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 2,850 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 3,900 | $0.00 | -- |
| Exercise | Common Stock | 17,037 | $0.00 | -- |
| Exercise | Common Stock | 2,850 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 40,431 shares (Direct);
Common Stock — 4,772 shares (Indirect, by Spouse);
Performance Restricted Stock Units — 77,090 shares (Direct);
Restricted Stock Unit — 49,474 shares (Direct);
Restricted Stock Unit — 5,474 shares (Indirect, by Spouse)
Footnotes (1)
- Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.72 to $75.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Grant to reporting person's spouse of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
FAQ
What did Ionis Pharmaceuticals (IONS) executive Joseph Baroldi report in this Form 4?
The filing reports vesting of restricted stock units into Ionis common stock, automatic sales of some shares to cover tax withholding, and new grants of performance and time-based restricted stock units to EVP and Chief Business Officer Joseph Baroldi and his spouse.
What performance restricted stock units did Joseph Baroldi receive from Ionis Pharmaceuticals (IONS)?
He received a grant of 25,800 performance restricted stock units on 01/15/2026 under the Ionis Amended and Restated 2011 Equity Incentive Plan. These units may vest at the end of a three-year performance period based on Ionis’s relative total shareholder return, and the 25,800 units represent the maximum that may be earned.
What time-based restricted stock units were granted to Joseph Baroldi and his spouse by Ionis Pharmaceuticals (IONS)?
On 01/15/2026, Baroldi received 9,675 restricted stock units directly and his spouse received 3,900 restricted stock units. These units vest in four equal annual installments and each unit represents a contingent right to receive one Ionis common share or its cash equivalent.